Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 24:12:989-995.
doi: 10.2147/CLEP.S254516. eCollection 2020.

The Association Between Rhabdomyolysis, Acute Kidney Injury, Renal Replacement Therapy, and Mortality

Affiliations

The Association Between Rhabdomyolysis, Acute Kidney Injury, Renal Replacement Therapy, and Mortality

Finn Erland Nielsen et al. Clin Epidemiol. .

Abstract

Background: We examined the association between creatine phosphokinase level in rhabdomyolysis patients and risk of acute kidney injury, renal replacement therapy, and death within 30 days.

Methods: The cohort included patients admitted with rhabdomyolysis from November 1, 2011 to March 1, 2014. Rhabdomyolysis was defined as a creatine phosphokinase level higher than 1000 U/L. Information on laboratory variables was obtained from a laboratory database. Medical data were obtained from registries. Acute kidney injury was defined according to the Kidney Disease Improving Global Outcome (KDIGO) guidelines. The 30-day risk of outcomes was estimated using the cumulative incidence method. Spline regression applied to imputed datasets with adjustment for baseline variables was used to assess the appropriateness of the categorization chosen for creatine phosphokinase (1000-5000 U/L, 5001-15,000 U/L, and 15,000+ U/L).

Results: The study included 1027 patients (58.2% male) with a median age of 73.5 years. The median creatine phosphokinase level at rhabdomyolysis diagnosis was 2257 U/L (interquartile range=1404-3961 U/L). The 30-day risks of acute kidney injury according to the three creatinine phosphokinase levels were 42% (95% CI=38-45%), 44% (95% CI=36-52%), and 74% (95% CI=57-85%), respectively, and the risks of renal replacement therapy for the three levels were 3% (95% CI=2-5%), 4% (95% CI=2-7%), and 11% (3-23%), respectively. The 30-day risk of death was 17% (95% CI=14-20%), 16% (95% CI=11-22%), and 11% (95% CI=3-23%), respectively. With increasing creatine phosphokinase levels, the spline plots supported the increasing risk of acute kidney injury and renal replacement therapy, as well as a decreasing risk of death. However, the risk estimates for renal replacement therapy and death were imprecise.

Conclusion: Elevated initial creatine phosphokinase values were associated with an increased risk of acute kidney injury, while estimates of the risk of renal replacement therapy and death were imprecise.

Keywords: acute kidney injury; cohort study; mortality; renal replacement therapy; rhabdomyolysis; spline plots.

PubMed Disclaimer

Conflict of interest statement

Finn Erland Nielsen reports grants from Naestved-Slagelse-Ringsted Research Foundation (03-10-2014), Inger Bonnéns Fond (02-03-2015), and Snedkermester Sophus Jacobsen & Hustru Astrid Jacobsens Fond (24-09-2015), during the conduct of the study. The authors report no other potential conflicts of interest for this work.

Figures

Figure 1
Figure 1
Flowchart of patients who met inclusion or exclusion criteria for the study.
Figure 2
Figure 2
Restricted cubic spline plots of the association among creatine phosphokinase with acute kidney injury, renal replacement therapy, and death. Adjusted for gender, age, Charlson Comorbidlty Score, primary diagnosis at hospital discharge, surgery during the index admission, medication use up to 1 year prior to the index admission, and laboratory results for the baseline period and on the date of the index admission. Solid lines denote the hazard ratios. Dashed lines denote confidence intervals.

References

    1. Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve. 2015;51(6):793–810. doi: 10.1002/mus.24606 - DOI - PMC - PubMed
    1. Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15:58–69. - PMC - PubMed
    1. Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Critical Care. 2014;18:224–231. doi: 10.1186/cc13897 - DOI - PMC - PubMed
    1. Shapiro ML, Baldea A, Luchette FA. Rhabdomyolysis in the Intensive Care Unit. J Intensive Care Med. 2012;27(6):335–342. doi: 10.1177/0885066611402150 - DOI - PubMed
    1. Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48(6):749–756. doi: 10.1515/CCLM.2010.151 - DOI - PubMed

LinkOut - more resources